Company Overview
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Trades at a P/E of 0.1, below the sector median of 24.8.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -39.70% |
| 6 Months: | +61.11% |
| 3 Months: | +85.11% |
| 1 Month: | +2.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.09 · Neutral
P/E of 0.13 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 50.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VOR Vor Biopharma Inc. R3KPHARMA | 24.36 | 0.13 | $1.32B | 0.00% | -84.67% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.29M | 274.28M | 28.11M | 35.96M | 35.16M |
| Operating Income | -7.88M | -8.04M | -11.79M | -13.73M | -18.38M | -18.60M | -22.80M | -21.79M | -24.10M | -30.42M | -32.17M | -35.32M | -32.33M | -29.04M | -28.51M | -33.29M | -274.28M | -28.11M | -35.96M | -35.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.47M | -272.25M | -28.11M | -35.94M | -35.13M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.49M | -1.57B | -812.68M | 1.72B | -219.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.85M | -8.04M | -11.79M | -13.72M | -18.37M | -18.55M | -22.74M | -21.66M | -23.79M | -28.43M | -29.98M | -33.19M | -30.80M | -27.84M | -27.56M | -32.49M | -1.57B | -812.68M | 1.72B | -219.59M |
| Diluted EPS | - | - | - | - | -0.50 | -0.50 | -0.61 | -0.58 | -0.63 | -0.43 | -0.45 | -0.49 | -0.45 | -0.41 | -8.05 | -5.21 | -251.20 | -121.63 | - | -5.11 |
| R&D Expense | 6.17M | 5.97M | 8.14M | 8.94M | 12.97M | 12.93M | 15.28M | 15.33M | 16.88M | 21.91M | 23.90M | 27.61M | 24.32M | 21.82M | 21.82M | 26.70M | 261.50M | 14.14M | - | 17.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 93.42M | 126.04M | 121.19M | 371.64M |
| Operating Income | -43.37M | - | -93.42M | -126.04M | -121.19M | -371.64M |
| EBITDA | - | - | -90.89M | -122.54M | -117.66M | -368.75M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -92.09M | -117.86M | -116.91M | -695.98M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -43.34M | - | -92.09M | -117.86M | -116.91M | -695.98M |
| Diluted EPS | - | - | -46.60 | -35.00 | -34.03 | -70.50 |
| R&D Expense | 31.62M | 47.53M | 64.55M | 94.31M | 93.31M | 321.53M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 75.91M | - | 299.37M | 198.13M | 142.89M | 464.13M |
| Current Assets | - | - | - | 236.95M | 140.80M | 96.51M | 458.11M |
| Cash & Equivalents | - | 48.54M | - | 57.71M | 31.36M | 81.95M | 396.49M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 27.64M | - | 48.76M | 47.40M | 46.23M | 628.44M |
| Current Liabilities | - | 10.21M | - | 13.12M | 15.57M | 18.61M | 25.17M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 38.91M | 35.66M | 31.83M | 3.00M |
| Total Equity | -17.43M | -59.06M | - | 250.61M | 150.72M | 96.66M | -164.31M |
| Shares Outstanding | - | - | - | 3.30M | 3.39M | 6.24M | 38.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.29M | - | -85.14M | -100.29M | -99.66M | -142.71M |
| Investing Cash Flow | -4.16M | - | -94.09M | 71.01M | 96.86M | -48.80M |
| Financing Cash Flow | 82.53M | - | 117.14M | 2.94M | 53.39M | 503.81M |
| Capital Expenditure | -4.16M | - | -8.46M | -1.07M | -229.00K | -941.00K |
| Free Cash Flow | -40.45M | - | -93.61M | -101.36M | -99.89M | -143.65M |
| Net Change in Cash | - | - | -62.09M | -26.35M | 50.59M | 312.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 73.4% | - | -36.7% | -78.2% | -120.9% | 423.6% |
| ROCE % | -66.0% | - | -32.6% | -69.0% | -97.5% | -84.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 9.59% | 5.67M | $121.40M |
| 2 | FMR, LLC | 8.34% | 4.93M | $105.55M |
| 3 | FCPM III Services B.V. | 6.96% | 4.12M | $88.11M |
| 4 | Blackrock Inc. | 5.86% | 3.47M | $74.22M |
| 5 | Venrock Adviser, LLC | 5.14% | 3.04M | $65.09M |
| 6 | State Street Corporation | 4.42% | 2.62M | $55.99M |
| 7 | Frazier Life Sciences Management, L.P. | 4.30% | 2.54M | $54.44M |
| 8 | RA Capital Management, L.P. | 4.06% | 2.40M | $51.40M |
| 9 | Vanguard Capital Management LLC | 3.52% | 2.08M | $44.60M |
| 10 | Caligan Partners, LP | 3.25% | 1.93M | $41.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VOR
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTFBhRDVZQkxnRTQtMkdTUzdBVmJhckVMTFhVMUFLSWlmSkxXdk1hQ1dJbHZlSzhObFh1OUk3SVVXTmRtOWFOYXQ1WWRCZ2o?oc=5" target="_blank">Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History</a>&…
Vor Biopharma Stock Price Forecast. Should You Buy VOR? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE9PaWNSRVQwaFk5eldjUmE3S1YyRWlTaWlwNlpkUVdHT3VFNFgwOVpVd08xb2QxemVNenNvQXZZQmcxSWVyR0tB?oc=5" target="_blank">Vor Biopharma Stock Price Forecast. Should You Buy VOR?</a> …
A new trial for eye-related muscle weakness is planned for 2027. Vor Bio finished enrolling another. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNb3BEN2NfVlJXQ0R3REdXS3RoVUhYd1BrRHhEV1dMNmQ0SU1oTWNXRGFRand3MjZ5SXdnaHhIY2Q3ZWxKX2RYaEFJR192NFJhTTBhbnVVbXZkd0xTdUd4Vno0X3ZEMk5yT1pua0VzOGhhWm51SnA2eWFOdUVXQVNlcHdXc004NFRlUkdWMz…
Why (VOR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPTVRpTHRtRndXQ2ZpcENuZThvMkFXeHVpSVp2bThQblBNOTJwbWd4VDRZWVlvVEpPSk1oNVVzTUs4M053Qlg3ZmNZYklmbHczbC1hWWRIMEljS3JQYmUzZE9lRnpRS0xFOGZ3aU5EbEtodmpRay1FWGdwT1ppWmNVdnRUWmt2T3NwLW81c2…
Why Did Vor Biopharma (VOR) Stock Drop After Its Latest Update? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOYlEtbnEtZW1mOENvU3pIX3BfaW9HbzJNU0hqR2hfai1CTDUzaU85RnZoUkNucEkwMlFkVXR5aFpaa1lJd3N0NzNrVVcyclZOTmFlcmxMYmd4TWFCeE1hTC02QXo3Q196MDd3ZDdzX05hQ1N4TlFGOGM3emZxSWdHeERveGtJZWJhQS1xQX…
VOR Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBXMnUxLVk0MkVITGRVQi1NT3gxWWhUR1N3OFcxTHhRVWpiS0FaNXlPN2dUMEhvNDZ6Z0hqTWU1YlRCU1B5Um00dTFiNktyWTZobWNmVVF1Q2VwaTNLemcxckc1THdrQkZ4OG51YVlndE0xd0p0ZkZHZg?oc=5" target="_blank">VOR F…
VOR — Frequently Asked Questions
What is the current share price of Vor Biopharma Inc. (VOR)?
As of 2026-09-19 21:16 PDT, Vor Biopharma Inc. (VOR) trades at $24.36 on NasdaqGS. Its 52-week range is $6.86 to $48.72.
What is the market capitalisation of VOR?
Vor Biopharma Inc. (VOR) has a market capitalisation of $1.32B on NasdaqGS.
What is the P/E ratio of VOR?
VOR trades at a trailing price-to-earnings (P/E) ratio of 0.13. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -5.82.
Is VOR a good stock to buy?
This page provides a data-driven analysis of Vor Biopharma Inc. (VOR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.